Page 123 - ACCB 2020

Variantes del gen GBA en el Suroccidente Colombiano. Arturo-Terranova et al

19. Drugan C, Procopciuc L, Jebeleanu G, Grigorescu-Sido P, Dussau J, Poenaru L, et al. (2002). Enfer-
medad de Gaucher en pacientes rumanos: incidencia de las mutaciones y manifestaciones fenotípicas
más comunes. Eur J Hum Genet. ; 10 (9): 511–515.
20. Riboldi GM, & Di Fonzo AB. (2019). GBA, Gaucher Disease, and Parkinson’s Disease: From Genetic
to Clinic to New Therapeutic Approaches. Cells; 8(4): 364. http://doi.org/10.3390/cells8040364
21. López Reyes I, Esperón Álvarez AA, Lavaut Sánchez K, Puerta Díaz A, Santos González EN, Rubio
González T, et al (2019) Caracterización molecular del gen GBA en pacientes cubanos con enfermedad
de Gaucher. Rev gen com; 11(1)
22. Pomponio RJ, Cabrera-Salazar MA, Echeverri OY, Miller G, Barrera LA (2005). Guacher disease in
Colombia: mutation identifi cation and comparison to other Hispanic populations. Mol Genet Metab;
86: 466-72
23. Stirnemann J, Belmatoug N, Camou F, Serratrice C, Froissart R, Caillaud C,et al . (2017). A Review
of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments. Int J Mol Sci; 17;18(2).
http://doi.org/10.3390/ijms18020441.
24. Goker-Alpan O, Hruska K, Orvisky E, Kishanani P, Stubblefi eld BK, Schiffmann R et al (2005). Diver-
gent phenotypes in Gaucher disease implicate the role of modifi ers.J Med Genet; 42(6):e 37
25. Kumar K, Ramirez A, Gobel A, Kresojevic N, Svetel M, Lohmann K, et al (2013). Glucocerebrosidase
mutations in a Serbian Parkinson’s disease population. European Journal of Neurology., 20: 402–405
26. Liu G, Boot B, Locascio JJ, Jansen IE, Winder-Rhodes S, Eberly S, et al (2016). Specifi cally, neuro-
pathic Gaucher’s mutations accelerate cognitive decline in Parkinson’s. Ann Neurol; 80(5), 674–685.
https://doi.org/10.1002/ana.24781
27. Paciottia S, Persichettia E , Pagliardini S, Deganutoc M, Rosano C et al. (2012). First pilot newborn
screening for four lysosomal storage diseases in an Italian region: Identifi cation and analysis of a puta-
tive causative mutation in the GBA gene Clinica Chimica Acta; 413: 23–24, 20
28. Goker-Alpan O, Schiffmann R, Park J, Stubblefi eld B, Tayebi N, Sidransky E. (2003). Phenotypic
continuum in neuronopathic gaucher disease: an intermediate phenotype between type 2 and type 3. J
Pediatr.; 143(2) 273-276
29. Chan A, Holleran W, Ferguson T, Crumrine D, Goker-Alpan O, Schiffman R, et al. (2011). Skin ul-
trastructural fi ndings in type 2 Gaucher disease: Diagnostic implications. Mol Genet Metab; 104 (4):
631-636
30. Z. Kato, S. Fukuda, S. Tomatsu, H. Vega, T. Yasunaga, A. Yamagishi, et al.(1997). A novel common
missense mutation G301C in the N-acetylgalactosamine-6-sulfate sulfatase gene in mucopolysaccha-
ridosis IVA, Hum. Genet. 101 (1): 97–101
31. Moors, T.E., Paciotti, S., Ingrassia, A. et al. (2019) Characterization of Brain Lysosomal Activities in
GBA-Related and Sporadic Parkinson’s Disease and Dementia with Lewy Bodies. Mol Neurobiol 56,
1344–1355. https://doi.org/10.1007/s12035-018-1090-0
32. Siebert M, Bock H, Michelin-Tirelli K, Coelho J, Giugliani R, Saraiva-Pereira ML. (2011). Novel Mu-
tations in the Glucocerebrosidase Gene of Brazilian Patients with Gaucher Disease. JIMD R; 9:7-16.
http://doi.org/10.1007/8904_2012_174
33. J.A. Ruskey, L. Greenbaum, Lé. Roncière, A. Alam, D. Spiegelman, C. Liong, O.A. et al (2018) In-
creased yield of full GBA sequencing in Ashkenazi Jews with Parkinson’s disease. Eur J Med Genet;
62(1):65-69. http://doi.org/10.1016/j.ejmg.2018.05.005

123
Rev. Asoc. Col. Cienc.(Col.), 2020; 32: 115-123.